-66%

est. 2Y upside i

HealthcareSeries D+

Rank

#3814

Sector

Molecular Diagnostics / Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Medium

Given the sky-high entry multiple of 16.6x revenue, even optimistic scenarios imply negative returns after adjusting for likely dilution.

Last updated: July 3, 2026

Bull (10%)-11%

Natera holds its multiple at 12x due to strong revenue growth and market leadership, but even so, the high entry multiple limits upside. After 20% dilution, equity value declines by ~11%.

Base (50%)-56%

Multiple converges to 7x, top of public comp range, resulting in a 36% decline before dilution; with 20% dilution, equity loses over half its value.

Bear (40%)-93%

Multiple compresses to 3x due to competitive pressure from Guardant and CareDx, driving a 73% decline before dilution; after dilution, equity is essentially wiped out.

Est. time to liquidity~4.0 years

Preference Stack Risk

low

Funding Intensity

1230%

Preferred stock of $283M is only 0.7% of current valuation, so it does not impair common equity in any plausible downside scenario.

Dilution Risk

high

Company not profitable and may need to raise capital within 2 years, potentially diluting by 20%+.

Secondary Liquidity

limited

Secondary market exists at the same valuation, indicating some liquidity but at a high price.

Other — 163 roles

View all 163 open roles at Natera →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Natera's data — designed to show you've done your homework.

  • 1

    “How does Natera plan to defend its market share against Guardant Health's similar liquid biopsy tests?”

  • 2

    “What is the path to profitability given the high operating costs and capital intensity?”

  • 3

    “How would you value this equity grant relative to public company offers, considering the illiquidity premium?”

Community

Valuation Sentiment

Our model estimates -66% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.